Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GLAXO WELLCOME SEREVENT WITH CORTICOSTEROIDS MAY SUBSTITUTE FOR A DOUBLE DOSE OF CORTICOSTEROIDS -- NHLBI GUIDELINES; CONTROL OF NOCTURNAL SYMPTOMS CITED

Executive Summary

Glaxo Wellcome's long-acting beta2-agonist Serevent is suitable for concomitant use with inhaled corticosteroids for the treatment of moderate persistent asthma, according to new asthma guidelines issued by the National Heart, Lung & Blood Institute. "Moderate persistent" asthma is a new category in the revised NHLBI guidelines.

You may also be interested in...



FDA Pediatric Drug Division Director Will Be GSK’s Shirley Murphy

Former GlaxoSmithKline NeuroHealth Specialty Division VP Shirley Murphy, MD, will become the first director of FDA's Division of Pediatric Drug Development effective Sept. 9

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel